RT Journal Article
SR Electronic
T1 Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e005684
DO 10.1136/jitc-2022-005684
VO 10
IS 11
A1 Khushalani, Nikhil I
A1 Vassallo, Melinda
A1 Goldberg, Judith D
A1 Eroglu, Zeynep
A1 Kim, Younchul
A1 Cao, Biwei
A1 Ferguson, Robert
A1 Monson, Kelsey R
A1 Kirchhoff, Tomas
A1 Amato, Carol M
A1 Burke, Paulo
A1 Strange, Ann
A1 Monk, Emily
A1 Gibney, Geoffrey Thomas
A1 Kudchadkar, Ragini
A1 Markowitz, Joseph
A1 Brohl, Andrew S
A1 Pavlick, Anna
A1 Richards, Alison
A1 Woods, David M
A1 Weber, Jeffrey
YR 2022
UL http://jitc.bmj.com/content/10/11/e005684.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.